Unlock instant, AI-driven research and patent intelligence for your innovation.
Immunoadjuvant
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of immune adjuvant and tumor vaccine, applied in the field of immune adjuvant
Inactive Publication Date: 2005-07-27
CELL MEDICINE
View PDF1 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
As far as the prior art is concerned, if the tumor tissue or tumor cells containing complex and diverse tumor antigens are physically denatured in the body of the same type of animal, and then the immune adjuvant is administered to the denatured tissue, it is still None of the immune adjuvants were effective in eliciting an antitumor immune response against surviving tumor cells
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
example 1
[0040] Example 1: Liver Cancer Proliferation Inhibitory Effect of the Tumor Vaccine of the Present Invention
[0041] A. Materials and methods
[0042] 1. Preparation of immune adjuvants
[0043] 1) 25% human serum albumin solution (HAS, Baxter Albumac, Bacter) was diluted to 2.5% with sterile water, and adjusted to pH 2.5 with 4N HCl.
[0044] 2) Mix this 2.5% human serum albumin solution with heparin solution (Nobo Hiparin injection 1000, 1000 units / ml, about 7.69mg / ml or less, Aventis Pharmaceuticals Co., Ltd.) in various ratios to determine the heparin solution the most appropriate mixing ratio. The so-called most appropriate mixing ratio is to make microparticles with a certain mixing ratio at the beginning, centrifuge at a speed of 2500rpm (1300g) for 15 minutes, and then use protein analysis kit 1 (BioRad Laboratories, Tokyo, Japan) to quantify the concentration of the supernatant. Protein content, if more than 99.9% of the mixed protein is embedded in the particles,...
example 2
[0062] Example 2: Anti-tumor recurrence effect of micronized tuberculin administered to tumor tissue coagulated by microwave
[0063] A. Materials and methods
[0064] 1. Prepare micronized tuberculin according to item 1. of Example 1.
[0065] 2. Subcutaneously inject 1 × 10 6 A lung cancer cell of the same type (Lewis lung cancer cell line), by the 8th day, the subcutaneous lung cancer tissue basically reached 75mm 3 When the patient was anesthetized with pentobarbital sodium, the skin near the lung cancer tissue was incised, and a single-ball electrode for Microtaze endoscopy (E-24N, particle size 2.4mm) was inserted into the cancer tissue from here.
[0066] 3. Connect this electrode to Microtaze (HSE-8M type, produced by Azwell Company), and irradiate it with 10W power microwave for 3 minutes, so that the cancer tissue appears to be completely thermally coagulated.
[0067] 4. Suture the wound, and on the 10th day, mix tuberculin solution (25ng refined tuberculin disso...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Property
Measurement
Unit
particle diameter
aaaaa
aaaaa
Login to View More
Abstract
An immunoadjuvant which can efficiently exhibit potent adjuvant activity and avoid conditions undesirable for living bodies, and comprises precipitates formed by coacervation of (a) a soluble protein (provided that a soluble protein contained in tuberculin is excluded), and (b) a mucopolysaccharide, and further comprises (c) a soluble protein contained in tuberculin wherein said (c) is coprecipitated with the precipitates.
Description
technical field [0001] The present invention relates to immune adjuvants. Background technique [0002] Tuberculin has long been used as a reagent for detecting the history of Mycobacterium tuberculosis infection, or as a reagent for positive conversion after administration of Mycobacterium bovis BCG (hereinafter referred to as BCG). It has been reported that if the purified tuberculin obtained by refining the protein component of tuberculin by ammonium sulfate precipitation method is used, even if it is repeatedly administered to the human body, it will always appear in the tuberculin skin test. Some enhanced effects (Singh, D. etal., Am. J. Respir. Crit. Care Med. 2001, Sep 15; 164 (6): 962-4), but it will not cause excessive skin inflammation, which is extremely safe. [0003] The present inventors have found that in vivo administration of solidified or micronized tumor tissue together with at least one cytokine or a cytokine inducer can effectively induce an anti-tumor...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More